Bayer stock gains as Apollo and KKR close EUR 3 billion contraceptives deal

Published on 09/16/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock rose on Xetra on September 16, 2026, after Apollo and KKR closed a EUR 3 billion capital solution tied to the company’s contraceptives business. The move follows Bayer’s push to ease litigation and balance-sheet pressure while its Crop Science division posted strong 2025 figures.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) traded higher on Xetra on September 16, 2026, with the shares recently quoted around EUR 49 and up about 1 percent intraday, as investors reacted to the closing of a EUR 3 billion capital solution for the company’s long-acting reversible contraceptives business announced the same day.

Apollo and KKR inject EUR 3 billion into Bayer’s LARC unit

According to GlobeNewswire on September 16, 2026, funds managed by Apollo and affiliates, joined by KKR as a significant minority participant, completed a EUR 3 billion capital solution for Bayer by investing equity into a newly established entity that holds Bayer’s long-acting reversible contraceptives (LARC) business.

In this structure, Bayer retains a majority stake in the new entity and continues to exercise full operational control over the LARC business, meaning the transaction is designed as a funding and partnership solution rather than a full divestment, which may reassure investors who value the long-term growth potential of contraceptive products while addressing balance-sheet concerns.GlobeNewswire

Stock moves higher on Xetra amid DAX support

Per Xetra data cited by German financial portal finanzen.ch on September 16, 2026, Bayer stock was trading at EUR 49.14 around 12:29 p.m. local time, up 0.9 percent on the day, after opening the session at EUR 48.54 and reaching an intraday high of EUR 49.37, with around 283,209 shares changing hands at that point.finanzen.ch

A separate DAX overview from public broadcaster tagesschau showed Bayer at EUR 49.34 with a gain of 1.29 percent as of about 13:11 on September 16, 2026, placing the stock among the stronger names in the blue-chip index and underlining that the positive reaction to the capital solution came in a generally supportive German equity environment.tagesschau

Recent performance and valuation backdrop

A valuation review by Simply Wall St published on September 16, 2026, noted that Bayer stock recently closed at EUR 48.71 and has gained 81.3 percent over the past 12 months, a move that naturally increases investor focus on how much revenue and earnings the share price is being asked to support.Simply Wall St

In that context, Bayer’s Crop Science division reported revenue of EUR 21.6 billion and EBITDA before special items of EUR 4.19 billion in fiscal year 2025, as highlighted in a sector comparison article dated September 15, 2026, which shows that even after the share’s strong 12-month rally, investors are still anchoring their expectations in sizable operating cash flows from core businesses like seeds and crop protection.Aktiencheck

Analyst view and litigation overhang

An overview of recent commentary on Bayer’s Roundup litigation and share price noted that following a recent court hearing on the proposed Roundup settlement, the stock had declined about 1.2 percent but remained supported by renewed analyst interest; in particular, British investment bank Barclays raised its price target from EUR 60 to EUR 70 in September while maintaining a Buy rating, signaling that at least one major house still sees upside despite legal uncertainties.Stock-World

Legal risk remains a central factor: a Reuters report republished via a U.S. legal news outlet on September 15, 2026, stated that Bayer’s Monsanto unit is urging a Missouri judge to approve a proposed USD 7.25 billion Roundup settlement that would cover existing and future cancer claims, with payouts ranging from USD 10,000 to USD 165,000 per person and about 65,000 claims outstanding, underscoring both the scale of the exposure and the potential for a clearer financial path if the deal is approved.Missouri Lawyers Media

Closing price signal for Bayer stock

Based on the latest completed Xetra session, Bayer stock closed at EUR 48.71 on September 15, 2026, representing a 1.26 percent decline for that day compared with the prior close, on a volume of about 2,000,716 shares; the subsequent rebound toward the EUR 49 mark on September 16, 2026 shows that investors are digesting both the newly closed EUR 3 billion capital solution and ongoing litigation headlines while keeping the shares firmly within the upper half of their recent trading range.